Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Dusseldorf - Delayed Quote EUR

Pharmaron Beijing Co Ltd (17Q1.DU)

Compare
1.3300
-0.0200
(-1.48%)
At close: April 17 at 7:30:23 PM GMT+2
Loading Chart for 17Q1.DU
  • Previous Close 1.3500
  • Open 1.3600
  • Bid 1.3200 x --
  • Ask 1.4000 x --
  • Day's Range 1.3200 - 1.3600
  • 52 Week Range 1.3000 - 2.3000
  • Volume 0
  • Avg. Volume 0
  • Market Cap (intraday) --
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Apr 25, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Recent News: 17Q1.DU

View More

Performance Overview: 17Q1.DU

Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

17Q1.DU
21.30%
SSE Composite Index (000001.SS)
2.24%

1-Year Return

17Q1.DU
20.36%
SSE Composite Index (000001.SS)
6.59%

3-Year Return

17Q1.DU
20.36%
SSE Composite Index (000001.SS)
2.54%

5-Year Return

17Q1.DU
20.36%
SSE Composite Index (000001.SS)
15.44%

Compare To: 17Q1.DU

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 17Q1.DU

View More

Valuation Measures

Annual
As of 4/17/2025
  • Market Cap

    4.29B

  • Enterprise Value

    4.67B

  • Trailing P/E

    11.07

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.62

  • Price/Book (mrq)

    1.46

  • Enterprise Value/Revenue

    3.20

  • Enterprise Value/EBITDA

    11.61

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    --

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 17Q1.DU

View More

Company Insights: 17Q1.DU

Research Reports: 17Q1.DU

View More